酪氨酸激酶抑制剂减量可有效维持慢性髓性白血病主要分子学缓解
该回顾性真实世界研究纳入246例因不可耐受不良事件而在达到主要分子学缓解(MR3)后接受低于标准剂量(LD)酪氨酸激酶抑制剂(TKI)治疗的慢性髓性白血病(CML)患者。
要点
- 多数至少达MR3的CML患者可安全接受低剂量TKI维持治疗。
- 需警惕进展和 new 突变事件,低剂量TKI策略需保持监测。
核心结论
- 多数至少达到MR3的CML患者接受低剂量TKI可安全维持缓解,且不影响TFR实现。
研究设计与样本
- 回顾性真实世界研究,纳入246例因不可耐受不良事件在达到MR3后接受低于标准剂量TKI治疗的CML患者。
主要发现
- 1例在低剂量TKI治疗期间进展为急变期。
- 2例出现新ABL激酶域突变(T315I和V299L),其中1例末次随访时在替代低剂量TKI下达到深度分子学缓解。
临床怎么用
- 对因不可耐受不良事件而减量的CML患者,低剂量TKI可作为维持MR3的策略。
- 低剂量TKI期间需警惕疾病进展和新发ABL激酶域突变。
局限性
- 回顾性真实世界研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted therapy for chronic myeloid leukaemia (CML) has allowed for a near-normal patient life-expectancy; however, quality of life and aggravation of existing co-morbidities have posed new treatment challenges. In clinical practice, TKI dose reduction occurs frequently, often on multiple occasions, because of intolerance. We conducted a retrospective 'real-world practice' review of 246 patients receiving lower than standard dose (LD) TKI after the achievement of major molecular response (MR3), because of intolerable adverse events. In 274 of 298 cases of dose reduction (91·9%), MR3 was maintained at median follow-up of 27·3 months. One patient progressed to blast crisis while on LD TKI. Two patients developed two new ABL kinase domain mutations (T315I and V299L), of whom one had achieved deep molecular response on an alternative LD TKI at last follow-up. Seventy-six patients eventually discontinued LD TKI and the two-year treatment-free remission (TFR) rate in these patients was 74·1%. The majority of patients with CML in at least MR3 appear to be safely managed with LD TKI, although three of 246 patients had new events (progression and new mutation), indicating that this approach requires vigilance. TKI LD does not prevent the achievement of TFR in this patient population.
引用
- Claudiani S, Apperley JF, Szydlo R, et al. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2020. PMID: 33368155. doi:10.1111/bjh.17286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。